Skip to main content

New enhanced aPTT coagulation diagnostics

Ref-Nr: TA-UKE281


Our new diagnostic solution offers an enhanced way to perform aPTT coagulation tests, based on the highly specific activation of the F-XII. Our newly designed antibody allows an even more robust diagnostic tool for a test run millions of times every year.


Blood coagulation has major relevance in medical interventions. In this light, coagulation tests run million times yearly.

Several diagnostic tests are currently used to detect the coagulation state in patients, including PT (extrinsic) and aPTT (intrinsic) assays.

aPTT, or activated partial thromboplastin time, particularly assesses the FXII-related blood clotting. While the role of FXII in the coagulation cascade has been widely proven, the activation mechanism still posed some questions at molecular level.

The activation of FXII is usually triggered by the addition of silicates, which causes several limitations, in particular limited sensitivity and low specificity due to interferents.


Our innovation presents a newly designed antibody, which allows a very specific activation of the coagulation cascade through binding to the FXII.

We have identified a highly conserved target sequence of the FXII, which is responsible for the specific activation of the protein.

Through the specific interaction with this short peptide, the general activation with negatively charged particles, and the related limitations, is avoided.

Due to the mentioned advantages, this innovation opens the door to a reliable and robust diagnostic kit for this important and highly frequent determination of blood agglutination time in patients.


Based on the identification of the FXII binding domain, we are presenting a binding molecule, which precisely triggers the activation of FXII.

Our binding antibody binds highly specifically to the active domain of the protein, thus offering an excellent platform for its implementation as an analytical test tool.

The characteristics of our system fit very well to the requirements of an analysis kit:


  • High specificity
  • Simple measurement
  • No need of previous incubation
  • All components present in solution


  • Coagulation
  • Blood test


  • R&D Cooperation
  • Transfer of rights
  • Licensing


Dr. Francisco Blanco
Harburger Schloßstraße 6-12
21079 Hamburg




  • EP anhängig


FXII, Specific triggering, Intrinsic blood coagulation

Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr